X

Legal Notices

Disclaimer

ADVERTISING MATERIAL
The material contained on this Web site is provided for informational purposes only and does not constitute legal advice. The publication and receipt of any information contained on this Web site does not create an attorney-client relationship with Barash Law LLC or with any of our attorneys. Readers should not act upon any information on this site without seeking professional legal counsel. While the information on this Web site is maintained and periodically updated for accuracy, this information may contain omissions or errors for which we disclaim any and all liability.

Privacy Statement

Barash Law LLC does not collect identifying information from visitors to its Web site unless the information is provided by the visitor or the visitor's internet browser. We will only respond to direct inquiries, and will use information collected from internet browsers for the sole purpose of monitoring Web site usage. We do not share Web site data with outside third-parties. Barash Law LLC is not responsible for the privacy practices or content of any links to other Web sites contained in our Firm’s Web site. 

If you have any questions or concerns regarding this Privacy Statement, please contact us at info@ebarashlaw.com

Moving in the Right Direction: Cocrystals and the FDA

Read More

Using Solid Form Patents to Protect Pharmaceutical Products — Part I

Read More

Using Solid Form Patents to Protect Pharmaceutical Products — Part II

Read More

NEWS & EVENTS

EVENTS
AAPS eChalk Talk
Emergency Use Authorizations of Coronavirus Vaccines – Similarities and Differences between and EUA and Approval and Legal Ramifications of potential Vaccine Injury
February 17th, 2021
11:15AM ET
Emergency Use Authorizations as we know them now were borne out of the terror attacks on 9/11 and subsequent anthrax mail incidents and came into law in 2004 and have been amended in 2013 and again in 2016.  As of 1/1/2021, two vaccines have been authorized for use in the United States, each under an EUA.  This talk will explore the history of the EUA, the changes made to the EUA, and how it is being utilized today.  The talk will also discuss the differences between EUAs and Approvals as well as the federal government’s absorption of damages from vaccine injuries – who and what is covered and what are the limitations.
Register
EVENTS
AI Driven Drug Repositioning and Repurposing Conference:
AI and Pharmaceutical Solid Form Patent Strategies for Repurposing Pharmaceutical Assets
April 21st, 2021
11:15AM ET
‍
Eyal Barash of Barash Law LLC will be a featured speaker at this years AI Driven Drug Repositioning and Repurposing Conference. Eyal will discuss the importance of pharmaceutical solid forms in drug development and repurposing programs and how they can be used in patent strategies. He will also discuss the potential impact of AI on such patent strategies. Eyal will also be featured on a panel discussion with Alan Jiang of Xtalpi, and Kevin McLaren of Brannon Sowers & Cracraft PC. They will discuss the importance of AI and IP in drug discovery and development.
More Info

QUESTIONS ANSWERED

What is a solid form?

A solid form is the solid representation of a chemical compound.  Examples include polymorphs, salts, solvates, hydrates, cocrystals, and amorphous solids.

Read More
Why patent solid forms?

Solid forms are compositions of matter and Orange-Book listable as drug substance.  When the science is right, patenting follows.

Read More
How do you patent a solid form?

The same rules apply to solid forms as to any other inventions.  Careful attention should be paid to the kinds and quality of data used in solid form patents.

Read More

WHAT WE DO

pharmaceutical patents

Orange-Book Listable Patents Add Value

deals


Intellectual Property as Deal Currency

ip strategy and execution

A Strategy Requires a Realistic Plan

in-house
counsel

Legal Functionality as a Business Driver
© 2016 Barash Law LLC
Contact Us
Legal Notices